Valuation
- Market cap
- 5,052,199,000
- Revenue TTM
- $0
- Net income TTM
- $-183,790,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.04
Trading
- Volume
- 1,598,700
- Avg volume
- 2,201,124
- Day's range
- $36.86 – $38.14
- Shares out
- 134,367,000
- Stochastic %K
- 39%
- Beta
- 2.19
- Analysts
- Strong Sell
- Price target
- $69.39
Company profile
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the...
Show more
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 212 220 6633
- Website
- https://definiumtx.com
- Address
- One World Trade Center, Suite 8500, New York, United States
Latest news
No headlines yet.
